Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:ADMA NASDAQ:RCKT NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$84.68+0.7%$78.44$47.86▼$107.37$4.70B0.31570,367 shs238,410 shsADMAADMA Biologics$15.18-0.5%$15.81$13.50▼$25.67$3.62B0.473.32 million shs5.56 million shsRCKTRocket Pharmaceuticals$3.85+2.9%$3.40$2.19▼$18.17$415.43M0.63.16 million shs1.24 million shsVKTXViking Therapeutics$34.42+1.5%$28.57$18.92▼$81.73$3.87B0.644.90 million shs4.38 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%-2.66%+8.01%+18.75%-3.98%ADMAADMA Biologics0.00%+5.71%-0.91%-15.71%-3.25%RCKTRocket Pharmaceuticals0.00%+3.77%+20.69%+22.61%-78.11%VKTXViking Therapeutics0.00%+2.65%+37.19%0.00%-43.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$84.68+0.7%$78.44$47.86▼$107.37$4.70B0.31570,367 shs238,410 shsADMAADMA Biologics$15.18-0.5%$15.81$13.50▼$25.67$3.62B0.473.32 million shs5.56 million shsRCKTRocket Pharmaceuticals$3.85+2.9%$3.40$2.19▼$18.17$415.43M0.63.16 million shs1.24 million shsVKTXViking Therapeutics$34.42+1.5%$28.57$18.92▼$81.73$3.87B0.644.90 million shs4.38 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%-2.66%+8.01%+18.75%-3.98%ADMAADMA Biologics0.00%+5.71%-0.91%-15.71%-3.25%RCKTRocket Pharmaceuticals0.00%+3.77%+20.69%+22.61%-78.11%VKTXViking Therapeutics0.00%+2.65%+37.19%0.00%-43.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.86Moderate Buy$113.0833.54% UpsideADMAADMA Biologics 3.00Buy$27.6782.26% UpsideRCKTRocket Pharmaceuticals 2.33Hold$16.67332.90% UpsideVKTXViking Therapeutics 2.81Moderate Buy$85.62148.74% UpsideCurrent Analyst Ratings BreakdownLatest RCKT, VKTX, ACLX, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025RCKTRocket PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/24/2025ACLXArcellxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025ADMAADMA BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)10/24/2025VKTXViking TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025VKTXViking TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$80.00 ➝ $75.0010/23/2025VKTXViking TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$98.00 ➝ $102.0010/23/2025VKTXViking TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$105.0010/23/2025VKTXViking TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/21/2025VKTXViking TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell10/16/2025ACLXArcellxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$129.0010/14/2025RCKTRocket PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M43.51N/AN/A$8.41 per share10.07ADMAADMA Biologics$426.45M8.49$0.54 per share28.05$1.48 per share10.26RCKTRocket PharmaceuticalsN/AN/AN/AN/A$5.08 per shareN/AVKTXViking TherapeuticsN/AN/AN/AN/A$7.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)ADMAADMA Biologics$197.67M$0.8617.6522.00N/A44.06%41.01%28.47%11/6/2025 (Estimated)RCKTRocket Pharmaceuticals-$258.75M-$2.51N/AN/AN/AN/A-65.11%-55.99%11/6/2025 (Estimated)VKTXViking Therapeutics-$109.96M-$2.12N/AN/AN/AN/A-28.23%-27.36%N/ALatest RCKT, VKTX, ACLX, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A11/6/2025Q3 2025ADMAADMA Biologics$0.16N/AN/AN/A$131.20 millionN/A11/6/2025Q3 2025RCKTRocket Pharmaceuticals-$0.48N/AN/AN/A$0.33 millionN/A10/22/2025Q3 2025VKTXViking Therapeutics-$0.67-$0.81-$0.14-$0.81N/AN/A8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q2 2025RCKTRocket Pharmaceuticals-$0.57-$0.59-$0.02-$0.62$4.36 millionN/A8/6/2025Q2 2025ADMAADMA Biologics$0.14$0.15+$0.01$0.14$121.77 million$121.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AADMAADMA BiologicsN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81ADMAADMA Biologics0.215.332.78RCKTRocket Pharmaceuticals0.056.396.39VKTXViking TherapeuticsN/A25.8625.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ADMAADMA Biologics75.68%RCKTRocket Pharmaceuticals98.39%VKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ADMAADMA Biologics3.50%RCKTRocket Pharmaceuticals24.76%VKTXViking Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableADMAADMA Biologics530238.63 million230.28 millionOptionableRCKTRocket Pharmaceuticals240107.90 million81.19 millionOptionableVKTXViking Therapeutics20112.44 million107.84 millionOptionableRCKT, VKTX, ACLX, and ADMA HeadlinesRecent News About These CompaniesViking Therapeutics' (VKTX) "Sell (D-)" Rating Reaffirmed at Weiss Ratings5 hours ago | marketbeat.comJP Morgan Maintains Viking Therapeutics (VKTX) Overweight RecommendationOctober 25 at 4:47 AM | msn.comViking Therapeutics (NASDAQ:VKTX) Shares Gap Up - Here's What HappenedOctober 24 at 11:35 AM | marketbeat.comMorgan Stanley Maintains Viking Therapeutics (VKTX) Overweight RecommendationOctober 24 at 11:26 AM | msn.comViking Therapeutics (NASDAQ:VKTX) Price Target Cut to $75.00 by Analysts at JPMorgan Chase & Co.October 24 at 9:44 AM | marketbeat.comWhat is Leerink Partnrs' Estimate for VKTX FY2029 Earnings?October 24 at 7:50 AM | marketbeat.comNew VK2735 Dosing Trial Might Change the Case for Investing in Viking Therapeutics (VKTX)October 24 at 6:26 AM | finance.yahoo.comViking Therapeutics, Inc. $VKTX Shares Sold by International Assets Investment Management LLCOctober 24 at 4:42 AM | marketbeat.comViking Therapeutics (NASDAQ:VKTX) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPSOctober 23 at 6:00 PM | marketbeat.comViking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales NilOctober 23 at 3:56 PM | zacks.comViking Therapeutics (NASDAQ:VKTX) Stock Rating Lowered by Zacks ResearchOctober 23 at 7:14 AM | marketbeat.comViking Therapeutics, Inc. (VKTX) Q3 2025 Earnings Call TranscriptOctober 22, 2025 | seekingalpha.comViking Therapeutics options imply 7.6% move in share price post-earningsOctober 22, 2025 | msn.comViking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateOctober 22, 2025 | prnewswire.comEarnings Preview For Viking TherapeuticsOctober 21, 2025 | benzinga.comViking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with ObesityOctober 21, 2025 | prnewswire.comViking Therapeutics (VKTX): Exploring Valuation as Investor Optimism Grows for Obesity Drug Pipeline and Earnings ReleaseOctober 19, 2025 | uk.finance.yahoo.comViking Therapeutics (VKTX) Receives a Buy from OppenheimerOctober 17, 2025 | finance.yahoo.comTrump jab sinks NVO, LLY, VKTX, AMGN, ALTOctober 17, 2025 | nai500.comNViking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key FactsOctober 17, 2025 | zacks.comViking Therapeutics (NASDAQ:VKTX) Trading Down 3.4% - Time to Sell?October 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRCKT, VKTX, ACLX, and ADMA Company DescriptionsArcellx NASDAQ:ACLX$84.68 +0.61 (+0.73%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$84.76 +0.07 (+0.09%) As of 10/24/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.ADMA Biologics NASDAQ:ADMA$15.18 -0.07 (-0.46%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$15.14 -0.04 (-0.26%) As of 10/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Rocket Pharmaceuticals NASDAQ:RCKT$3.85 +0.11 (+2.94%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.88 +0.03 (+0.88%) As of 10/24/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.Viking Therapeutics NASDAQ:VKTX$34.42 +0.50 (+1.47%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$34.48 +0.06 (+0.19%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
